GRI Bio, Inc.
GRI
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.2M
$1.85
▼ -2.63%
P/E
—
Mkt Cap
$4.2M
52-Wk Range
$1.36–$64.12
52-Week Range
$1.36 - $64.12
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 96.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Natural Killer T cell targeting platform with 500+ compound library
- Novel oral drug formulations addressing unmet needs in rare fibrotic diseases
- Focused pipeline strategy reducing development complexity and time-to-market
- Specialized expertise in immune modulation with differentiated mechanism of action
Bear Case
1 risk
- Low volatility (beta -0.6).
Growth
Stable outlook
Phase IIa clinical trial advancement of GRI-0621 in idiopathic pulmonary fibrosis
Value
Valuation data unavailable
Momentum
Stable
+3.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GRI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 13, 2026
Reported EPS of -$1.61 vs -$1.20 consensus (-34.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-34.2%
Revenue trend · last 8Q
—
—
—
—
—
—
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 26
Q1 26
Q2 26
$0
$0
$22.5M
$0
$6.3M
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GRI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related